Join Growin Stock Community!

Sana biotechnology, inc.SANA.US Overview

US StockHealthcare
(No presentation for SANA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

SANA AI Insights

SANA Overall Performance

SANA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

SANA Recent Performance

-1.66%

Sana biotechnology, inc.

0.05%

Avg of Sector

-0.31%

S&P500

SANA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

SANA Key Information

SANA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

SANA Profile

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Price of SANA

SANA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

SANA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.74
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.88
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
5.74
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is SANA's latest earnings report released?

    The most recent financial report for Sana biotechnology, inc. (SANA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating SANA's short-term business performance and financial health. For the latest updates on SANA's earnings releases, visit this page regularly.

  • How much debt does SANA have?

    As of the end of the reporting period, Sana biotechnology, inc. (SANA) had total debt of 82.24M, with a debt ratio of 0.19. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does SANA have?

    At the end of the period, Sana biotechnology, inc. (SANA) held Total Cash and Cash Equivalents of 107.55M, accounting for 0.25 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is SANA's EPS continuing to grow?

    According to the past four quarterly reports, Sana biotechnology, inc. (SANA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.16. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of SANA?

    Sana biotechnology, inc. (SANA)'s Free Cash Flow (FCF) for the period is -29.33M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 47.54% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.